Amarantus Bioscience Holdings Inc., of San Francisco, said it closed a $3 million investment from an institutional investor who will be issued series H convertible preferred stock valued at $3.3 million (including 10 percent original issue discount) and five-year warrants exercisable for 13.2 million shares of common stock at $0.40 each.